Application of plasma-derived exosome in preparation of medicine for improving or treating oral diseases

By isolating and preparing exosomes from plasma, inhibiting the release of inflammatory factors and chemokines, the problem of limited efficacy in the treatment of oral ulcers in the prior art is solved, rapid healing and inflammation of oral ulcers is achieved, and exocrine Potential for the body in the treatment of oral diseases.

CN119074768AActive Publication Date: 2024-12-06SHANDONG QILU STEM CELL ENG +1

Patent Information

Application Number
CN202411258617.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-12-06
Estimated Expiration
2044-09-09

AI Technical Summary

Technical Problem

The prior art has limited efficacy in the treatment of oral diseases such as oral ulcers, and lacks effective therapies to relieve symptoms and promote healing.

Method used

By isolating and preparing exosomes from plasma, the release of inflammatory factors and chemokines is inhibited and the healing of damaged tissues in oral diseases is promoted. Specific steps include collecting plasma, ultracentrifugation of exosomes, and obtaining exosomes with a particle size of 50-250 nm by gradient centrifugation and washing, for in vitro cell contact to regulate cell activity.

Benefits of technology

It significantly accelerates the healing process of oral ulcers, reduces inflammation progression, promotes oral epithelial cell proliferation and mucosal damage repair, and demonstrates good biological effects and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074768A_ABST
    Figure CN119074768A_ABST
Patent Text Reader

Abstract

The invention discloses an application of a plasma-derived exosome in preparation of a medicine for improving or treating oral diseases. The plasma-derived exosome has good biological effects of inhibiting inflammation, promoting angiogenesis and accelerating lesion healing, and the healing of mucosal injury is accelerated by inhibiting the release of inflammatory factors and chemotactic factors, so that the progress of inflammation is reduced. In addition, the plasma-derived exosome can promote human oral epithelial cell proliferation and scratch healing, and has a good effect in the aspect of improving oral diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and in particular relates to the use of plasma-derived exosomes in the preparation of drugs for improving or treating oral diseases. Background Art

[0002] Oral disease is a general term for a variety of diseases involving the oral cavity and surrounding tissues, including gingivitis, periodontitis, stomatitis or oral ulcers. Oral disease is a relatively common disease that can cause discomfort to infected patients and affect their quality of life. In severe cases, it may interfere with patients' daily lives, such as diet and speech, and thus endanger their mental health. There are many causes of oral diseases, such as microorganisms, wounds, and low immune function.

[0003] Oral ulcers are a common oral mucosal disease. They are painful and cause a burning sensation. However, the etiology of oral ulcers is complex, and clinical treatments are mainly local anti-inflammatory and analgesic, including the use of analgesics, hormones, gargles, and low-intensity laser therapy, but the efficacy is limited. Therefore, it is of great clinical significance to seek effective therapies to relieve oral ulcer symptoms and promote lesion healing. Summary of the invention

[0004] In order to solve at least some of the problems in the prior art, the present invention prepares exosomes by plasma separation, which accelerates the healing of damaged tissues in oral diseases by inhibiting the release of inflammatory factors and chemokines, thereby slowing down the progression of the disease. Specifically, the present invention includes the following contents.

[0005] A first aspect of the present invention provides a use of plasma-derived exosomes in the preparation of a medicament for improving or treating oral diseases.

[0006] In certain embodiments, according to the use of the present invention, the oral disease refers to a disease associated with upregulation of pro-inflammatory factors and / or downregulation of anti-inflammatory factors.

[0007] In certain embodiments, according to the use of the present invention, the proinflammatory factors include at least one of eotaxin, IL-12p70, IL-5, IP-10, IL-1α, IL-18, TNF-α, MIP-1α, IL-2, Fractalkine, IL-1β and IL-17.

[0008] In certain embodiments, according to the use of the present invention, the anti-inflammatory factors include IL-4 and / or IL-10.

[0009] In certain embodiments, according to the use of the present invention, the oral disease refers to a disease associated with oral epithelial cell proliferation, expression of keratin CK5 and / or CK13.

[0010] In certain embodiments, according to the use of the present invention, the particle size of the exosomes is 50-250 nm.

[0011] In certain embodiments, according to the use of the present invention, the plasma-derived exosomes are prepared by plasma extraction and / or ultracentrifugation.

[0012] In certain embodiments, according to the use of the present invention, the plasma-derived exosomes are prepared by the following steps:

[0013] (1) Collecting plasma;

[0014] (2) Isolation of plasma-derived exosomes.

[0015] In certain embodiments, according to the use of the present invention, the separation comprises gradient centrifugation.

[0016] A second aspect of the present invention provides a method for regulating the activity of oral cavity-derived cells in vitro, comprising the step of contacting plasma-derived exosomes with cells in vitro.

[0017] The plasma-derived exosomes of the present invention have good biological effects of inhibiting inflammation, promoting angiogenesis and accelerating lesion healing. They accelerate the healing of mucosal injuries by inhibiting the release of inflammatory factors and chemokines, thereby reducing the progression of inflammation. In vitro experiments have confirmed that the plasma-derived exosomes of the present invention can promote human oral epithelial cell proliferation and scratch healing. In short, the plasma-derived exosomes of the present invention have a good effect in improving oral diseases, and can be used as a promising treatment method to regulate, for example, the regeneration and repair of mucosal injuries. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 The characterization of UCBP-Exo is shown. In the figure, A is a TEM image of UCBP-Exo, scale bar: 100 nm; B is a nanoparticle tracking analysis (NTA) image of UCBP-Exo; C is a nanoflow cytometry (nFCM) analysis image of UCBP-Exo; D is a Western blot detection of the marker protein of UCBP-Exo.

[0019] Figure 2The in vivo toxicity evaluation of UCBP-Exo is shown. A is the histopathological images of the heart, liver, spleen, lung and kidney collected from the control group and the UCBP-Exo group, scale bar: 300 μm; B is the blood routine examination of the control group and the UCBP-Exo group; C is the performance of various blood biochemical indicators under different treatment groups, ns (p>0.05).

[0020] Figure 3 The therapeutic effect of UCBP-Exo in the rat oral ulcer model is shown. Figure A shows the observation of using UCBP-Exo to restore the oral mucosal defect of rats on the 2nd and 4th days. Scale bar: Figure 4 mm, 6 mm in the lower figure; B is the injury healing rate after 2 or 4 days of treatment with UCBP-Exo; C is the histological observation of oral mucosal defects in rats restored by UCBP-Exo for 2 and 4 days, scale bar: 400 μm; D is the multiple fluorescent immunohistochemistry (mIHC) staining after 2 or 4 days of treatment with different UCBP-Exo, scale bar: 500 μm; E is the multiple detection of cytokines and chemokines in the serum of rats with different treatments, ns (p>0.05), *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

[0021] Figure 4 The mechanism of UCBP-Exo promoting the healing of oral mucosal defects is shown. A is a heat map of differentially expressed genes (DEGs) in rat mucosal tissue using gene expression fold changes in the control group and UCBP-Exo group; B is a bubble map showing the inflammation-related KEGG pathways in mucosal tissues in the UCBP-Exo treatment group and the control group; C is a volcano map analysis of DEGs between different groups in mucosal tissues; D is the DEGs of the UCBP-Exo treatment group and the control group in GO enrichment analysis; E is a Western blot analysis of IL6 and CK5 in mucosal tissues treated for 4 days; F is the mRNA expression of inflammatory and cytokeratin markers in rat oral mucosa treated for 4 days by RT-qPCR, ns (p>0.05), *p<0.05, **p<0.01.

[0022] Figure 5The figure shows the biological effect of UCBP-Exo on HOECs. Figure A shows the cell viability of human oral epithelial cells (HOECs) in different groups on day 1, day 2, and day 3. The columns in each group in the figure are control group, low-dose group, and high-dose group from left to right. *p<0.05 compared with the control group on day 1, #p<0.05 compared with the control group on day 2, &p<0.05 compared with the control group on day 3, &&p<0.01; B is the scratch test of HOECs after different treatments, and the scale bar is 400μm; C is the quantitative analysis of wound closure rate by measuring the gap size; D is a heat map of DEGs of HOECs using gene expression fold changes between the control group and the UCBP-Exo group; E is the genomic enrichment analysis (GSEA) of DEGs after HOECs treated with or without UCBP-Exo for 24 hours, NES indicates normalized enrichment score, *p<0.05, **p<0.01. DETAILED DESCRIPTION

[0023] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0024] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that the upper and lower limits of the scope and each intermediate value therebetween are specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0025] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as commonly understood by those skilled in the art to which the invention belongs. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials related to the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0026] application

[0027] One aspect of the present invention provides the use of plasma-derived exosomes in the preparation of a medicament for improving or treating oral diseases.

[0028] In the present invention, examples of plasma include but are not limited to venous plasma, such as cubital venous plasma, hand venous plasma, cord plasma (CBP) of human umbilical cord blood (HUCB), etc. In a preferred embodiment, the plasma is cord plasma.

[0029] In the present invention, the oral disease refers to a disease associated with upregulation of pro-inflammatory factors and / or downregulation of anti-inflammatory factors, examples of which include but are not limited to gingivitis, periodontitis, stomatitis or oral ulcers. In a preferred embodiment, the oral disease is an oral mucosal disease. In another preferred embodiment, the oral disease is an oral ulcer.

[0030] In the present invention, the pro-inflammatory factors include but are not limited to one or a combination of Eotaxin, IL-12p70, IL-5, IP-10, IL-1α, IL-18, TNF-α, MIP-1α, IL-2, Fractalkine, IL-1β and IL-17. In a preferred embodiment, the plasma-derived exosomes of the present invention can downregulate pro-inflammatory factors.

[0031] In the present invention, the anti-inflammatory factors include but are not limited to IL-4 and / or IL-10. In a preferred embodiment, the plasma-derived exosomes of the present invention can upregulate the anti-inflammatory factors.

[0032] In the present invention, the oral disease refers to a disease related to oral epithelial cell proliferation, expression of keratin CK5 and / or CK13. In a preferred embodiment, the plasma-derived exosomes of the present invention can promote the expression of keratin CK5 and / or CK13.

[0033] In the present invention, the particle size of the exosomes is 50-250 nm, preferably 70-220 nm, further preferably 90-190 nm, further preferably 100-160 nm, more preferably 100-130 nm, for example 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130 nm.

[0034] The term "improvement or treatment" used in the present invention refers to improving the condition of a subject's disease or dysfunction before or after the condition occurs (e.g., promoting wound healing). Compared to an untreated reference group under the same conditions, the degree of relief or prevention is at least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95% or 100% as measured by any standard technique.

[0035] In the present invention, the plasma-derived exosomes are prepared by plasma extraction and / or ultracentrifugation.

[0036] In a preferred embodiment, the plasma-derived exosomes are prepared by the following steps: (1) collecting plasma; (2) isolating the plasma-derived exosomes. In a specific embodiment, the separation in step (2) comprises ultracentrifugation.

[0037] In a specific embodiment, the plasma-derived exosomes are prepared by the following steps: centrifuging the umbilical cord blood at 800-1500 g, preferably 900-1400 g, such as 900, 1000, 1100, 1200, 1300 g for 10-20 min, preferably 11-19 min, and preferably 12-18 min, such as 12, 13, 14, 15, 16, 17, 18 min to collect plasma, and then centrifuging the plasma at 2000-4000 g, preferably 2100-3900 g, and preferably 2200-3800 g, and further preferably 230 0-3700g, more preferably 2400-3600g, more preferably 2500-3500g, for example 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500g for centrifugation for 20-40min, preferably 21-39min, also preferably 22-38min, further preferably 23-37min, more preferably 24-36min, more preferably 25-35min, for example 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35min. The supernatant is then centrifuged at 9000-11000g, preferably 9200-10800g, further preferably 9400-10600g, more preferably 9600-10400g, for example 9600, 9700, 9800, 9900, 10000g, 10100g, 10200g, 10300g, 10400g for 20-40min, preferably 21-39min, also preferably 22-38min, further preferably 23-37min, more preferably 24-36min, more preferably 25-35min, for example 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35min. The product is then ultracentrifuged at 90000-110000 g, preferably 92000-108000 g, further preferably 94000-106000 g, more preferably 96000-104000 g, for example 96000, 97000, 98000, 99000, 100000 g, 101000 g, 102000 g, 103000 g, 104000 g for 80-100 min, preferably 81-99 min, also preferably 82-98 min, further preferably 83-97 min, more preferably 84-96 min, more preferably 85-95 min, for example 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95 min.The precipitated exosomes are washed twice with saline and centrifuged at 90000-110000 g, preferably 92000-108000 g, further preferably 94000-106000 g, more preferably 96000-104000 g, such as 96000, 97000, 98000, 99000, 100000 g, 101000 g, 102000 g, 103000 g, 104000 g for 60-80 min, preferably 61-79 min, also preferably 62-78 min, further preferably 63-77 min, more preferably 64-76 min, more preferably 65-75 min, such as 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 min, and then resuspended in saline. Exosomes were prepared by filtering the suspension through a filter (including but not limited to a 0.15-0.3 μm filter, such as a 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.30 μm filter). All operations were performed at 4°C.

[0038] The present invention also provides the use of plasma-derived exosomes in the preparation of soft tissue repair drugs.

[0039] method

[0040] In one aspect of the present invention, a method for regulating the activity of oral cavity-derived cells in vitro comprises the step of contacting plasma-derived exosomes with cells in vitro.

[0041] In the present invention, examples of in vitro cells include, but are not limited to, periodontal ligament cells, salivary gland cells, oral mucosal cells, oral epithelial cells, etc. In a specific embodiment, the in vitro cells are human oral epithelial cells.

[0042] In the present invention, the plasma-derived exosomes are derived from blood cells, which exhibit physiological functions similar to those of blood cells, mediate intercellular communication by delivering the encapsulated nucleic acids and proteins to the receptor cells, and can affect the receptor cells more effectively than transcription factors, thereby having good biological effects of inhibiting inflammation, promoting angiogenesis, and accelerating lesion healing. In a specific embodiment, the plasma-derived exosomes of the present invention are derived from umbilical cord blood. Exosomes derived from human umbilical cord blood have the characteristics of good biological safety, stability, easy storage, and easy large-scale production.

[0043] In the method for regulating the activity of oral-derived cells in vitro according to the present invention, the regulated activity also includes regulating the amount of genes / proteins. Preferably, the regulated amount of genes / proteins includes downregulation of chemokines CCL3, CXCL1, IL6 and IL-1β and upregulation of keratins CK5 and CK13.

[0044] Therefore, the present invention also provides a method for regulating the amount of cellular genes / proteins in vitro, which comprises the step of contacting cells with plasma-derived exosomes in vitro, wherein the amount of regulated genes / proteins comprises downregulation of chemokines CCL3, CXCL1, IL6 and IL-1β and upregulation of keratins CK5 and CK13.

[0045] Example 1

[0046] The preparation and characterization of plasma-derived exosomes are shown below.

[0047] 1. Preparation method

[0048] The cord blood was transferred to a 50 mL centrifuge tube and centrifuged at 1200 g for 15 min to collect plasma. The plasma was then centrifuged at 3000 g for 30 min. The supernatant was then centrifuged at 10000 g for 30 min, followed by ultracentrifugation at 100000 g for 90 min. The precipitated exosomes were washed twice with saline and centrifuged at 100000 g for 70 min, then resuspended in saline. Exosomes (UCBP-Exo) were prepared by filtering the suspension through a 0.22 μm filter. All operations were performed at 4 °C.

[0049] 2. Characterization

[0050] The morphology of UCBP-Exo was observed by transmission electron microscopy (TEM). The particle size of UCBP-Exo was determined by nanoparticle tracking analysis (NTA) and nanoflow cytometry (nFCM). The surface markers of UCBP-Exo, CD9, CD63, calnexin, and TSG101, were identified by Western blotting.

[0051] UCBP-Exo was derived from umbilical cord blood and obtained by ultracentrifugation. The double-layer membrane ultrastructure of UCBP-Exo was observed using transmission electron microscopy, and the results showed that it had a cup-shaped membrane structure with clear edges and morphology ( Figure 1 A). Nanoparticle tracking analysis showed that the particle size of UCBP-Exo was mainly concentrated at 112.9nm ( Figure 1 In addition, the results of nano-flow cytometry were similar to those of NTA ( Figure 1Finally, the transmembrane proteins CD63 and CD9, the cytoplasmic protein TSG101, and the negative protein Calnexin were detected by Western blotting. The data showed that the positive expression of CD63, CD9, and TSG101 and the negative expression of Calnexin were successfully detected ( Figure 1 D). The results show that the present invention successfully prepared UCBP-Exo and can be used for further research.

[0052] Example 2

[0053] The following exemplifies the effects of UCBP-Exo on wounds and ulcers.

[0054] 1. Experimental Methods

[0055] 1. Rat ulcer model and treatment

[0056] 4-6 week old SD rats were divided into 2 groups, i.e., control group (no UCBP-Exo treatment on the ulcer) and UCBP-Exo group (ulcer was treated by spraying liquid containing UCBP-Exo). After anesthesia by intraperitoneal injection of 100 mg / kg sodium pentobarbital, a 4.5 mm diameter filter paper impregnated with 50% glacial acetic acid was attached to the buccal mucosa on both sides of the oral cavity for 30 s, and then the residual glacial acetic acid was wiped off with a sterile cotton ball containing saline. 24 hours after surgery (0d), the lesions were treated accordingly every day for 4 consecutive days, during which time the ulcer lesions were evaluated and photographs were taken for observation. The lesion healing rate was measured using ImageJ software 2 and 4 days after treatment with or without UCBP-Exo. The lesion healing rate was calculated as follows: lesion healing rate = (initial lesion area - lesion area at the evaluation time point) / initial lesion area × 100%.

[0057] 2. Histological Analysis

[0058] Rats were killed 4 days after treatment, and major organs (heart, liver, spleen, lung, kidney) and buccal mucosal tissues around the lesions were collected, fixed in formalin, dehydrated, and embedded in paraffin. Then, the paraffin-embedded samples were sectioned. Finally, the sections were stained with hematoxylin-eosin (H&E) according to the established protocol and analyzed using K-viewer software to evaluate the in vivo UCBP-Exo toxicity and effects on injury healing.

[0059] 3. Blood test of rats

[0060] For routine blood tests, 1 ml of whole blood was collected and analyzed using a fully automated blood analyzer.

[0061] For blood biochemical examination, whole blood of rats was centrifuged at 3000 rpm for 10 minutes in a sodium heparin centrifuge tube and plasma was separated and analyzed using a biochemical analyzer Mindray BS-2000.

[0062] 4. Multiplex immunohistochemistry (mIHC) staining

[0063] The sections were incubated with antibodies CD31, IL6, and CK5 in sequence using the mIHC staining kit according to the instructions, and finally scanned using a laser confocal microscope. DAPI was used to mark cell nuclei, CD31 was used to assess angiogenesis, IL-6 was used to detect the degree of inflammation, and CK5 was used to assess epithelial regeneration.

[0064] The following primary antibodies were used: anti-CD31, anti-IL6, anti-CK5. Histological images were analyzed using LAS X.

[0065] 5. Detection of Rat Serum Cytokines

[0066] After 4 days of treatment, blood was collected from the two groups of rats and centrifuged at 3000 rpm for 15 min to obtain serum. Rat serum samples were assayed using the MILLIPLEX kit according to the manufacturer's instructions, and the results were read using Belysa software. The levels of cytokines in serum samples of each group were calculated using a standard curve.

[0067] 6. RNA sequencing (RNA-seq) and validation

[0068] For RNA-seq, rat buccal mucosal tissue was collected after 4 days of treatment, and HOECs were collected after 24 h of treatment. Total RNA was extracted using TRIzol reagent, magnetic beads with Oligo (dT) were selected for enrichment and purification, and then the purified mRNA was fragmented. The fragmented mRNA was then used as a template and reverse transcribed with random primers to synthesize the first and second strands of cDNA. Afterwards, the library was prepared by end repair, base A addition, sequencing adapter addition, magnetic bead screening to recover target fragments, and PCR amplification. Finally, the quality of the library was checked, and the qualified library was sequenced using the Illumina platform with a PE150 sequencing strategy.

[0069] For western blot validation, the buccal mucosal tissues from the lesions were thoroughly ground in liquid nitrogen, and the relative protein levels of IL6 and CK5 in the ulcer tissues with different treatments were detected. Briefly, protein lysates were added to the sample tissues, the protein concentration was detected, and the proteins were denatured. Then, electrophoresis, membrane transfer, blocking, antibody incubation, and protein detection were performed in sequence. Finally, β-actin was used as the total protein internal reference, and the protein expression of different groups was analyzed by Image Lab software.

[0070] For real-time quantitative PCR (RT-qPCR) validation, buccal mucosa samples were ground into powder in liquid nitrogen, and total RNA was extracted using TRIzol reagent. RNA was then reverse transcribed into cDNA using a reverse transcription kit. RT-qPCR was then performed using the QuantStudio3 system with a SYBR Green Master Mix kit. The primer sequences for CCL3, IL6, IL-1β, CK5, and CK13 genes are shown in Table 1, and GAPDH was used as an internal control gene.

[0071] Table 1 Primer sequences used for RT-qPCR analysis

[0072]

[0073] 7. Cell Proliferation Assay

[0074] The proliferation of HOECs was measured using the Cell Counting Kit-8 reagent. HOECs were seeded (1×10 4 Cells / well) were plated in 96-well plates and cultured overnight at 37°C with different treatments (PBS, 10 μg / mL UCBP-Exo, 50 μg / mL UCBP-Exo). On days 1, 2, and 3, 10% CCK-8 solution was added to each well and incubated at 37°C for 2 hours. OD values ​​were measured at 450 nm using a microplate reader. All experiments were performed at least three times.

[0075] 8. Scratch Wound Assay

[0076] HOECs were plated in 6-well plates and incubated until fully confluent. The monolayer of HOECs was gently scraped using a 200 μl pipette tip and rinsed three times with PBS to remove detached cells. After incubation for 0 and 12 hours with or without different concentrations of UCBP-Exo in the culture medium, wound closure was observed using an inverted microscope. The wound closure rate was quantified by ImageJ software and calculated as follows: wound closure rate = (initial wound area-wound area at the evaluation time point) / initial wound area × 100%.

[0077] 2. Experimental Results

[0078] 1. In vivo toxicity evaluation of UCBP-Exo

[0079] To evaluate the biosafety of UCBP-Exo in vivo, UCBP-Exo was administered to rats by oral gavage and histological tests were first performed. No inflammation or histopathological abnormalities were observed in the heart, liver, spleen, lung, and kidney of the rats ( Figure 2A), indicating that UCBP-Exo did not cause significant organ damage in rats. Routine blood and blood biochemistry tests showed that UCBP-Exo treatment did not adversely affect hematological parameters compared with the control group ( Figure 2 In addition, no significant side effects were found during the entire UCBP-Exo treatment period, implying the safety of UCBP-Exo in in vivo treatment.

[0080] 2. Evaluation of the therapeutic effect of UCBP-Exo in a rat oral ulcer model

[0081] This example evaluates the effect of UCBP-Exo on oral ulcer healing. Rats were randomly divided into three groups, filter paper containing 50% glacial acetic acid was placed on the lower lip mucosa, and the lesions were treated with UCBP-Exo 24 hours after injury. By the fourth day of treatment, the oral ulcers in the UCBP-Exo group were basically healed. The oral mucosa of the UCBP-Exo-treated group was bright red, while in the control group, the lesions healed slowly and the mucosa was still significantly edematous ( Figure 3 H&E staining showed that in the control group, the lesion area showed little epithelialization and loose disorganized connective tissue, with diffuse inflammatory cell infiltration in the submucosal layer. In contrast, the UCBP-Exo group showed better mucosal healing, with intact thickened squamous epithelium and significantly reduced inflammatory cells compared with the control group ( Figure 3 C).

[0082] Angiogenesis reflects the degree of tissue reconstruction and mucosal function recovery. Multiple immunohistochemistry (mIHC) staining showed that the endothelial cell marker CD31 had a lower density in the control group, indicating a low level of angiogenesis. In contrast, the UCBP-Exo-treated group showed a significant increase in the vascularized area. IL6 was used to evaluate the inflammatory response during lesion treatment. The presence of a large number of IL6-positive cell infiltrations in the control group indicated that UCBP-Exo had anti-inflammatory activity, thereby contributing to the healing of damaged mucosal tissue. In addition, the expression of cytokeratin 5 (CK5) present in the epithelial layer was significantly increased in the UCBP-Exo group compared with the control group, confirming that UCBP-Exo treatment restored the original structure of the mucosa ( Figure 3 D).

[0083] As wound healing progresses, the secretion of cytokines at the site of injury changes. The following evaluation of the secretion of inflammatory factors, chemokines, and growth factors in the serum of rats after UCBP-Exo treatment revealed a significant increase in the secretion of proinflammatory factors and chemokines (such as TNFα, IL-1β, IL17, eotaxin, IL12p70, IL5, IP-10, IL-1α, MIP-1α, IL2, MCP-1, and leptin) in the control group. In addition, the concentrations of secreted anti-inflammatory and growth factors (including IL4, IL10, VEGF, G-CSF, RANTES, and EGF) were significantly increased in the UCBP-Exo-treated group compared with the control group ( Figure 3 The results showed that UCBP-Exo could promote epithelial tissue regeneration, angiogenesis and anti-inflammatory response, thereby improving the pathological structure of oral ulcers.

[0084] 3. Mechanism of UCBP-Exo in promoting healing of oral mucosal defects

[0085] In order to gain a deeper understanding of the intrinsic mechanism and potential downstream signaling pathways of UCBP-Exo in promoting the healing of oral mucosal lesions, RNA sequencing was performed on oral mucosal tissues treated with or without UCBP-Exo. Differentially expressed genes were analyzed in the mucosal tissues of the control group and the UCBP-Exo group, and the results showed that there were significant differences in the expression of genes in the two groups of tissues, indicating that UCBP-Exo significantly affected the physiological function of the lesions ( Figure 4 A).

[0086] Inflammation is an important stage in the wound healing cascade, and long-term inflammation is harmful. KEGG analysis showed that the TNF signaling pathway and cytokine-cytokine receptor interactions were significantly enriched after UCBP-Exo treatment. The TNF signaling pathway affects the development of inflammation by inducing immune cell proliferation and activation and regulating the release of chemokines. Cytokine-cytokine receptor interactions can trigger a variety of downstream signaling pathways that can participate in the regulation of cell growth, immune response, angiogenesis, and tissue repair, aiming to restore the homeostasis of the internal microenvironment. In summary, these data indicate that mucosal tissues treated with UCBP-Exo have a stronger immune activation effect than those in the control group ( Figure 4 B).

[0087] The volcano plot showed that the expression of chemokines CCL3, CXCL1, CXCL2 and inflammatory factors IL6 and IL-1β in the UCBP-Exo-treated group was downregulated compared with the control group. This further confirmed the anti-inflammatory effect of UCBP-Exo. As for the UCBP-Exo group, the enriched BP terms were mainly concentrated in the ATP metabolic process ( Figure 4D), indicating that UCBP-Exo may accelerate tissue healing by regulating cellular aerobic respiration. Based on the in-depth analysis of RNA-seq, we performed RT-qPCR and western blot experiments, and the results clearly showed that treatment of the mucosal defect area with UCBP-Exo reduced the expression levels of inflammatory factors and chemokines compared with the control group ( Figure 4 In conclusion, UCBP-Exo modulates immune signaling pathways to accelerate mucosal regeneration by reducing the release of inflammatory factors and chemokines.

[0088] 4. Biological effects of UCBP-Exo on HOECs

[0089] In order to study the effect of UCBP-Exo in vitro, 10 μg / mL (low concentration) and 50 μg / mL (high concentration) of UCBP-Exo were selected to treat HOECs. CCK8 assay showed that UCBP-Exo promoted the proliferation of HOECs after 1, 2, and 3 days of treatment ( Figure 5 A), indicating that UCBP-Exo is biocompatible for in vitro applications.

[0090] The scratch test showed that 12 hours after the scratch, the migration ability of HOECs treated with UCBP-Exo was significantly enhanced compared with that of HOECs treated with PBS in the control group ( Figure 5 B, C). In addition, the ability of UCBP-Exo to promote wound closure did not increase with increasing concentration, and effective healing could be achieved by applying only low concentrations of UCBP-Exo. The above results demonstrate the properties of UCBP-Exo in promoting HOECs migration in vitro, further confirming their potential applicability in the treatment of oral mucosal diseases.

[0091] In addition, DEGs analysis of HOECs in the control group and UCBP-Exo group showed significant differences in gene expression between the two groups, indicating that UCBP-Exo significantly affected the physiological functions of HOECs ( Figure 5 D). Gene set enrichment analysis revealed that genes involved in the assembly of mitochondrial respiratory chain complex IV were enriched in HOECs treated with UCBP-Exo, indicating that UCBP-Exo affects aerobic respiration and energy metabolism, thereby regulating the biological effects in HOECs ( Figure 5 E).

[0092] Conclusion

[0093] Oral diseases are prevalent and affect the daily quality of life of patients. However, traditional treatments have limited effects. The present invention prepares UCBP-Exo, which has good biocompatibility and anti-inflammatory activity in a rat oral ulcer model, thereby contributing to the healing of damaged epithelial tissue. UCBP-Exo can improve the pathological structure of the lesion area. In addition, RNA-seq showed that UCBP-Exo regulates immune signal transduction by reducing the release of inflammatory factors and chemokines, thereby accelerating the repair of mucosal damage. In vitro experiments showed that UCBP-Exo promoted the proliferation and scratch healing of HOECs, once again confirming the healing ability of UCBP-Exo at the cellular level. In summary, this example confirms that UCBP-Exo-based therapy has achieved good results in improving the recovery and regeneration of oral mucosal tissue, broadens the theory of oral and maxillofacial tissue engineering in the field of soft tissue repair, and shows that UCBP-Exo can be used as a promising treatment method to eliminate mucosal damaged tissue.

[0094] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit them; although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the above embodiments, or replace some of the technical features therein by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. Application of plasma-derived exosomes in the preparation of drugs for improving or treating oral diseases.

2. The use according to claim 1, characterized in that: The oral disease refers to a disease associated with upregulation of pro-inflammatory factors and / or downregulation of anti-inflammatory factors.

3. The use according to claim 2, characterized in that: The pro-inflammatory factors include at least one of Eotaxin, IL-12p70, IL-5, IP-10, IL-1α, IL-18, TNF-α, MIP-1α, IL-2, Fractalkine, IL-1β and IL-17.

4. The use according to claim 2, characterized in that: The anti-inflammatory factors include IL-4 and / or IL-10.

5. The use according to claim 1, characterized in that: The oral disease refers to a disease associated with oral epithelial cell proliferation and the expression of keratin CK5 and / or CK13.

6. The use according to claim 1, characterized in that: The particle size of the exosomes is 50-250 nm.

7. The use according to claim 1, characterized in that: The plasma-derived exosomes are prepared by plasma extraction and / or ultracentrifugation.

8. The use according to claim 1, characterized in that: The plasma-derived exosomes are prepared by the following steps: (1) Collecting plasma; (2) isolating exosomes from the plasma.

9. The use according to claim 8, characterized in that: The separation comprises gradient centrifugation.

10. A method for regulating the activity of oral-derived cells in vitro, characterized in that: The method comprises the step of contacting plasma-derived exosomes with in vitro cells, wherein the cell activity comprises cell proliferation and / or cell migration.

Citation Information

Patent Citations

  • Use of umbilical cord blood derived exosomes for tissue repair

    CN109414459A

  • Oral mucosal disease spray prepared by combining umbilical cord mesenchymal stem cell exosome with umbilical cord blood PRP

    CN115957185A

  • Extraction method and application of human plasma exosome

    CN116676261A

  • Plasma matrix-based biological material as well as preparation method and application thereof

    CN117462764A

  • The window cleaner phone case

    KR1020220117512A

Cited By

  • Method for improving lethality of umbilical cord blood-derived NK cells and application of method

    CN119842608A

  • A method for enhancing the killing ability of cord blood-derived NK cells and its application

    CN119842608B